Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Colon cancer
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Results 1-25 of 248 for your search:
Start Over
Quercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-114, NCI-2015-01705, NCT02195232
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CDR0000577892, NCI-2015-01484, NCI-2014-01372, SINGAPORE-07-32-LGI, SINGAPORE-ICR-02, ICR-02, SINGAPORE-ASCOLT, NCT00565708
Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 18 and over
Trial IDs: CO21, NCI-2015-01662, CAN-NCIC-CO21, CDR0000629834, NCT00819208
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-102, NCI-2012-00575, NCT01483027
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 50 to 75
Trial IDs: CB-17-01/06, NCI-2014-00316, 2012-003983-32, NCT01694966
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 2012-PT023, NCI-2013-00997, NCT01767857
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: CR107047, NCI-2016-00410, 2015-001630-21, 39039039STM4001, NCT02555878
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 18 and over
Trial IDs: NSABP C-13, NCI-2016-00467, 17808, NCT02664077
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO30182, NCI-2016-01102, 2016-000202-11, NCT02788279
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1302.3, NCI-2016-01340, 2015-003718-25, NCT02776683
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CanStem303C, NCI-2016-01385, 2016-001627-31, BB608-303CRC, NCT02753127
Combination Chemotherapy with or without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability
Status: Not yet active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A021502, NCI-2016-01417, NCT02912559
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Panitumumab and Bortezomib in Treating Patients With Advanced or Refractory Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2011-033, NCI-2013-00657, NCT01504477
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod Before Surgery in Treating Patients With Recurrent or Metastatic Colorectal Cancer That Can Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 10-131, NCI-2013-00076, NCT01545141
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-130-02, NCI-2013-01786, NCT01605318
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Capecitabine and Ziv-Aflibercept in Treating Patients with Refractory Solid Tumors or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00037688, NCI-2013-00472, NCT01661972
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients with Cancer Receiving Anti-Angiogenesis Therapy
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VARIMG0002, NCI-2013-00535, NCT01806675
Start Over